EFFECT OF PAROXETINE IN ANXIETY DISORDER AMONG SCHOOL DROPOUT TEENAGER IN SOUTH INDIAN POPULATION
Objective: Anxiety disorders are the most common group of psychiatric illnesses in children. This study is to observe the effectiveness of Paroxetine in anxiety disorder among teenagers in South India population using Hamilton Anxiety Rating Scale (HAM-A) and to screen the possible risk for paroxetine in anxiety disorder among teenagers.
Methods: This study is a prospective observational study that was conducted for a period of 6 mo. Of 84 teenage patients with anxiety disorder assessed using Hamilton Anxiety Rating Scale (HAM-A) were followed-up in an outpatient psychiatric ward. Study population includes both sexes, age group between 13 to 19 y, Teenage patient receiving paroxetine for anxiety disorder were included and patients unwilling to give written informed consent or assent form were excluded.
Results: Out of 84 patients the prevalence of symptoms before the drug treatment, 65 patients were falling in very severe category, which was assessed by HAM-A scale. Then reassessed with drug Paroxetine at week 4 and week 8. There was a drastic reduction in the prevalence of symptoms in week 8 than compared to week 4. A significant reduction in body weight was also observed during the study period. Among various side effects, nausea was the prominent risk found during the study.
Conclusion: The present study demonstrated that paroxetine is effective and well-tolerated for the treatment of various types of anxiety disorder in teenagers with few side effects.
2. Psychiatrists American psychiatric association. Available from: https://www.psychiatry.org/patients-families/anxiety-disorders. [Last accessed on 07 Apr 2020]
3. Nita V Bhatt. Medscape. Available from: https://emedicine.medscape.com/article/286227-overview. [Last accessed on 07 Apr 2020]
4. Ranna parekh. Psychiatric. Available from: https://www.psychiatry.org/patients-families/anxiety-disorders/what-are-anxiety disorders. [Last accessed on 07 Apr 2020].
5. BorwinBandelow, Leo Sher, Robertas Bunevicius, Eric Hollander, Siegfried Kasper, Joseph Zohar, et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Practice 2012;16:77–84.
6. Mehdi Sayyah, Fakher Rahim. Comparing the effect of second-generation antipsychotics versus selective serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a systematic review of the past, present, and future clinical trials. Asian J Pharm Clin Res 2017;10:150-16.
7. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50–5.
8. Nair MKC, Russell PSS, Mammen P. A dad 3: the epidemiology of anxiety disorders among adolescents in a rural community population in India. Indian J Pediatr 2013;80 Suppl 2:144-8.
9. Borwin Bandelow, Sophie Michaelis. Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci 2015;17:327–35.
10. Tae Suk Kim, Chi Un Pae, Su Jung Yoon, Won Myong Bahk, Jun Won Tae, Jeong Ho Chae, et al. Comparison of venlafaxine extended-release versus paroxetine for treatment of patients with generalized anxiety disorder. Psychiatry Clin Neurosci 2006;60:347-51.
11. Gülseren L, Gülseren S, Hekimsoy Z, Mete L. Comparison of fluoxetine and paroxetine in type II diabetes mellitus patients. Arch Med Res 2005;36:159–65.
12. Wagner KD, Berard R, Stein MB. Paroxetine improves social anxiety disorder in children and Adolescents. Arch Gen Psychiatry 2004;61:1153-62.
This work is licensed under a Creative Commons Attribution 4.0 International License.